Literature DB >> 20636420

In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

S Hatakeyama1, M Ozawa, Y Kawaoka.   

Abstract

We and others have previously isolated influenza B viruses with reduced sensitivity to neuraminidase (NA) inhibitors (oseltamivir and zanamivir) from patients who were never exposed to these drugs. It was unclear whether the NA substitutions found in these influenza B isolates arose spontaneously or were caused by selective pressure. Here, we obtained influenza B viruses with reduced NA inhibitor sensitivity by in vitro selection with NA inhibitors. We found that these viruses possessed the same NA substitutions as those previously found in viruses isolated from untreated patients. These results suggest that these NA substitutions were selected in patients who were treated with an NA inhibitor and that the resistant variants were then transmitted to others.
© 2010 The Authors. Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636420      PMCID: PMC2980859          DOI: 10.1111/j.1469-0691.2010.03313.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  16 in total

Review 1.  Resistance of influenza viruses to neuraminidase inhibitors--a review.

Authors:  J L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2000-07       Impact factor: 5.970

2.  In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.

Authors:  Ai Lee Cheam; Ian G Barr; Alan W Hampson; Jennifer Mosse; Aeron C Hurt
Journal:  Antiviral Res       Date:  2004-09       Impact factor: 5.970

3.  Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.

Authors:  J M Colacino; W G Laver; G M Air
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

4.  Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.

Authors:  K A Staschke; J M Colacino; A J Baxter; G M Air; A Bansal; W J Hornback; J E Munroe; W G Laver
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

5.  Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.

Authors:  P M Colman; P A Hoyne; M C Lawrence
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.

Authors:  J M Barnett; A Cadman; F M Burrell; S H Madar; A P Lewis; M Tisdale; R Bethell
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

7.  A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.

Authors:  Ellen Z Baum; Pamela C Wagaman; Linh Ly; Ignatius Turchi; Jianhua Le; Doris Bucher; Karen Bush
Journal:  Antiviral Res       Date:  2003-06       Impact factor: 5.970

8.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

9.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

Authors:  L V Gubareva; M N Matrosovich; M K Brenner; R C Bethell; R G Webster
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

10.  Sequential mutations in hemagglutinins of influenza B virus isolates: definition of antigenic domains.

Authors:  M Krystal; J F Young; P Palese; I A Wilson; J J Skehel; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

View more
  5 in total

Review 1.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

2.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 3.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

4.  Influenza B viruses circulated during last 5 years in Mongolia.

Authors:  Naranzul Tsedenbal; Altansukh Tsend-Ayush; Darmaa Badarch; Sarantuya Jav; Nymadawa Pagbajab
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

5.  I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.

Authors:  Jennifer L McKimm-Breschkin; Susan Barrett; Muhammad Azhar; Frank Y K Wong; Paul Selleck; Peter G Mohr; James McGrane; Mia Kim
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.